AnaptysBio Announces Third Quarter 2021 Financial Results
Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and GEMINI-1 Phase 3 trial initiated subsequent to FDA end-of-Phase 2...
Source: globenewswire.com
Stay updated with breaking news from Agonist Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and GEMINI-1 Phase 3 trial initiated subsequent to FDA end-of-Phase 2...